Rigel Pharmaceuticals (RIGL)

Finanzdaten der Rigel Pharmaceuticals-Aktie (RIGL)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	33.81%78.70	58.82	69.80	69.46	101.69
Cost Of Revenue	85.08%8.53	4.61	5.96	4.75	4.50
	6.50%32.64	30.65	-	-	-
Selling, General, and Administrative	6.50%32.64	30.65	-	-	-
Research and Development	19.57%13.96	11.68	-	-	-
Costs And Expenses	17.46%55.13	46.93	46.63	41.04	40.58
Operating Income/Loss	98.36%23.58	11.89	23.17	28.42	61.10
Income/Loss From Continuing Operations Before Tax	102.32%23.59	11.66	22.71	27.62	59.98
Income Tax Expense/Benefit	109.62%6.30	3.00	-245.35	-0.28	0.37
	99.79%17.29	8.65	268.07	27.90	59.61
Attributable To Parent	99.79%17.29	8.65	268.07	27.90	59.61
Basic Average Shares	0.70%18.54	18.41	0.08	18.04	17.89
Diluted Average Shares	0.59%19.57	19.69	0.46	19.16	18.16
Basic Earnings Per Share	97.87%0.93	0.47	14.88	1.55	3.33
Diluted Earnings Per Share	100.00%0.88	0.44	14.10	1.46	3.28